mRNA |
alisertib |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
3e-05 |
mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
3e-05 |
mRNA |
SKI-II |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
3e-05 |
mRNA |
BRD-K28456706 |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
3e-05 |
mRNA |
JQ-1 |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
4e-05 |
mRNA |
ISOX:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.15 |
5e-05 |
mRNA |
navitoclax:piperlongumine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.15 |
6e-05 |
mRNA |
PL-DI |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
6e-05 |
mRNA |
AZ-3146 |
CTRPv2 |
pan-cancer |
AAC |
0.15 |
6e-05 |
mRNA |
tretinoin:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.15 |
9e-05 |